A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Vir Biotechnology, Inc.
VIR
$1.2B
Mkt Cap
$8.69
-6.96%
Vir Biotechnology, Inc. (VIR) has a 5-year average return on invested capital (ROIC) of 25.4%. This indicates strong capital allocation and a potential competitive advantage.
Vir Biotechnology, Inc. (VIR) has a market capitalization of $1.4B. It is classified as a small-cap stock.
Vir Biotechnology, Inc. (VIR) does not currently pay a regular dividend.
Vir Biotechnology, Inc. (VIR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Vir Biotechnology, Inc. (VIR) generated $-397 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Vir Biotechnology, Inc. (VIR) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Vir Biotechnology, Inc. (VIR) reported earnings per share (EPS) of $-3.16 in its most recent fiscal year.
Overview and Strategy Powering the Immune System to Transform Lives. Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses. However, these threats have evolved sophisticated mechanisms to evade our immune defenses. When cancer cells or viruses successfully bypass our immune system, they have the potential to cause diseases that may be life-threatening. We are focused on developing therapies that enhance the immune system’s ability to overcome these evasion tactics, effectively powering the immune system to combat viruses and fight cancer.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 65M | - | - | - | 1.6B | 1.1B |
| Net Income | -443M | -438M | -522M | -615M | 516M | 529M |
| EPS | $-3.06 | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 |
| Free Cash Flow | -450M | -397M | -454M | -800M | 1.6B | -69M |
| ROIC | -108.9% | -45.7% | -38.1% | -33.5% | 162.2% | 82.1% |
| Gross Margin | - | - | - | - | 90.9% | 94.0% |
| Debt/Equity | 0.00 | 0.13 | 0.09 | 0.08 | 0.06 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -472M | -479M | -587M | -684M | 833M | 421M |
| Operating Margin | -720.8% | - | - | - | 51.6% | 38.4% |
| ROE | -54.5% | -45.7% | -38.1% | -33.5% | 29.4% | 49.2% |
| Shares Outstanding | 161M | 139M | 136M | 134M | 135M | 133M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | N/A | N/A | N/A | 1.1B | 1.6B | N/A | N/A | N/A | 65M |
| Gross Margin | N/A | N/A | N/A | N/A | 94.0% | 90.9% | N/A | N/A | N/A | N/A |
| R&D | 63M | 100M | 148M | 302M | 448M | 475M | 580M | 506M | 456M | 446M |
| SG&A | 22M | 29M | 38M | 71M | 161M | 162M | 174M | 119M | 92M | 91M |
| EBIT | -81M | -119M | -178M | -297M | 421M | 833M | -684M | -587M | -479M | -472M |
| Op. Margin | N/A | N/A | N/A | N/A | 38.4% | 51.6% | N/A | N/A | N/A | -720.8% |
| Net Income | -70M | -116M | -175M | -299M | 529M | 516M | -615M | -522M | -438M | -443M |
| Net Margin | N/A | N/A | N/A | N/A | 48.3% | 31.9% | N/A | N/A | N/A | -676.0% |
| Non-Recurring | 0 | -198K | -345K | 0 | 0 | 0 | 14M | 35M | 182K | -172K |
| Returns on Capital | ||||||||||
| ROIC | N/M | -61.9% | -142.2% | -52.3% | 82.1% | 162.2% | -33.5% | -38.1% | -45.7% | -108.9% |
| ROE | 181.7% | 93.4% | -142.7% | -52.4% | 49.2% | 29.4% | -33.5% | -38.1% | -45.7% | -54.5% |
| ROA | -39464.4% | -120.9% | -49.6% | -41.7% | 36.8% | 21.7% | -26.1% | -31.5% | -36.5% | -43.2% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -66M | -94M | -130M | -191M | -48M | 1.7B | -779M | -446M | -392M | -446M |
| Free Cash Flow | -69M | -102M | -139M | -197M | -69M | 1.6B | -800M | -454M | -397M | -450M |
| Owner Earnings | -71M | -101M | -142M | -223M | -137M | 1.6B | -910M | -539M | -453M | -505M |
| CapEx | 2.7M | 8.2M | 8.9M | 6.5M | 22M | 68M | 22M | 7.3M | 4.8M | 3.6M |
| Maint. CapEx | 255K | 1.6M | 3.3M | 4.4M | 5.3M | 6.8M | 19M | 15M | 12M | 12M |
| Growth CapEx | 2.5M | 6.6M | 5.6M | 2.1M | 17M | 61M | 2.1M | 0 | 0 | 0 |
| D&A | 255K | 1.6M | 3.3M | 4.4M | 5.3M | 6.8M | 19M | 15M | 12M | 12M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 4.1% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.8M | 5.1M | 8.7M | 28M | 84M | 102M | 111M | 78M | 49M | 47M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | N/A | -382M | -666M | -428M | -2.2B | -1.4B | -803M | -363M | -470M |
| Cash & Equiv. | 188M | 48M | 109M | 437M | 348M | 849M | 242M | 223M | 232M | 470M |
| Long-Term Debt | N/A | N/A | 900K | 700K | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -1.00 | -0.34 | 0.00 | 0.10 | 0.10 | 0.06 | 0.08 | 0.09 | 0.13 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | -1368.6 | -587.2 | -368.7 | -368.7 |
| Equity | -69M | -179M | 424M | 717M | 1.4B | 2.1B | 1.6B | 1.2B | 765M | 813M |
| Total Assets | 177K | 192M | 512M | 919M | 2.0B | 2.8B | 1.9B | 1.4B | 1.0B | 1.0B |
| Total Liabilities | 69M | 62M | 88M | 202M | 522M | 724M | 329M | 248M | 238M | 213M |
| Intangibles | N/A | 37M | 36M | 34M | 33M | 33M | 23M | 8.1M | 7.8M | 7.8M |
| Retained Earnings | N/A | -194M | -369M | -667M | -139M | 377M | -238M | -760M | -1.2B | -1.3B |
| Working Capital | N/A | 78M | 344M | 673M | 1.2B | 2.0B | 1.4B | 923M | 421M | 449M |
| Current Assets | N/A | 118M | 403M | 772M | 1.6B | 2.5B | 1.6B | 1.0B | 514M | 523M |
| Current Liabilities | N/A | 40M | 59M | 99M | 341M | 511M | 175M | 120M | 93M | 74M |
| Per Share Data | ||||||||||
| EPS | -32.45 | -15.12 | -1.62 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 | -3.16 | -3.06 |
| Owner EPS | -33.18 | -13.15 | -1.32 | -1.87 | -1.02 | 11.54 | -6.79 | -3.96 | -3.26 | -3.13 |
| Book Value | -32.02 | -23.38 | 3.94 | 6.02 | 10.73 | 15.43 | 11.87 | 8.44 | 5.52 | 5.04 |
| Cash Flow/Share | -30.84 | -12.28 | -1.20 | -1.60 | -0.36 | 12.35 | -5.81 | -3.28 | -2.83 | -2.67 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.2M | 7.7M | 107.6M | 119.0M | 133.5M | 134.7M | 134.0M | 136.3M | 138.6M | 161.2M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 9.9 | 6.5 | N/A | N/A | N/A | -2.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 2.1 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 3.7 | 4.7 | 3.7 | 1.6 | 0.9 | 0.9 | 1.1 | 1.7 |
| Price/Sales | N/A | N/A | N/A | N/A | 5.5 | 2.2 | N/A | N/A | N/A | 21.4 |
| FCF Yield | N/A | N/A | -8.8% | -5.9% | -1.3% | 47.8% | -58.0% | -44.6% | -47.7% | -32.1% |
| Market Cap | 0 | N/A | 1.6B | 3.3B | 5.3B | 3.3B | 1.4B | 1.0B | 832M | 1.4B |
| Avg. Price | 0.00 | N/A | 13.44 | 33.96 | 45.14 | 25.96 | 18.58 | 9.09 | 6.31 | 8.69 |
| Year-End Price | 0.00 | N/A | 12.37 | 28.11 | 39.38 | 24.80 | 10.29 | 7.47 | 6.00 | 8.69 |
Vir Biotechnology, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
The company's 5-year average ROIC is 25.4% with a gross margin of 92.5%. At current prices, the estimated annualized return to fair value is +18.7%.
Vir Biotechnology, Inc. (VIR) has a return on equity (ROE) of -45.7%. A negative ROE may indicate losses or negative equity.
Vir Biotechnology, Inc. (VIR) has a 5-year average gross margin of 92.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for Vir Biotechnology, Inc. (VIR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Vir Biotechnology, Inc. (VIR) has a book value per share of $5.52, based on its most recent annual SEC filing.